reviewed april 2026|next review october 2026|88 physicians psi has verified|49 published studies
Hepcidin
Hepcidin is a 25-amino-acid naturally occurring (the body's own) liver peptide hormone that controls systemic iron balance by binding and degrading ferroportin (the only known cellular iron exporter), with dysregulation causing both iron overload disorders (hemochromatosis from hepcidin deficiency) and inflammatory anemia (from hepcidin excess), and hepcidin mimetics currently in Phase III clinical trials.
Evidence landscape: 49 published studies
Published studies indexed under this compound. The broader hepcidin/ferroportin literature exceeds 6,700 papers. One of the most productive research fields in hematology and iron biology.
- 12 Human
- 11 Animal
- 26 Reviews
Hepcidin itself is not FDA-approved as a therapeutic. Hepcidin mimetics (rusfertide/PTG-300) are in Phase III trials for polycythemia vera. Anti-hepcidin antibodies are in clinical development for anemia of chronic disease. The hepcidin-ferroportin axis is an active drug development target.
Hepcidin is naturally occurring (the body's own), produced by liver hepatocytes. Not available as a supplement or commercial therapeutic. Hepcidin testing is becoming available through specialty laboratories but is not yet part of standard iron panels.
The most important discovery in iron metabolism in the past 25 years. Before hepcidin was identified in 2000-2001, systemic iron regulation was poorly understood. Over 6,700 published studies now establish hepcidin as the central hormonal controller of iron balance. The therapeutic pipeline targeting this pathway is one of the most active in peptide medicine.
PSI Assessment
Before hepcidin was discovered in 2000-2001, a basic question in medicine had no good answer: how does the body control iron levels? Iron is essential for oxygen transport and cellular function, but excess iron is toxic. The discovery of hepcidin provided the answer. This single 25-amino-acid liver peptide controls iron absorption from the gut, iron recycling from macrophages, and iron release from storage sites. When hepcidin is high (as in chronic inflammation), iron is trapped inside cells, explaining why infections and chronic disease cause anemia. When hepcidin is low (as in hemochromatosis), iron floods the bloodstream unchecked.
The master regulator of systemic iron metabolism. Controls all iron absorption and recycling through a single molecular interaction with ferroportin. Explains both iron overload and inflammatory anemia.
The mechanism is a single molecular interaction: hepcidin binds ferroportin, the only known cellular iron exporter, causing its internalization and degradation. When ferroportin is removed from cell surfaces, iron cannot exit enterocytes (gut absorption drops), macrophages (iron recycling drops), or hepatocytes (stored iron stays locked away). Hepcidin production is regulated by three main signals: iron status (BMP/SMAD pathway), inflammation (IL-6/STAT3 pathway), and erythropoietic demand (erythroferrone). This regulatory triad determines whether iron flows freely or is sequestered.
What the evidence supports
Hepcidin is the master regulator of systemic iron metabolism. This is among the most well-established findings in peptide endocrinology. Hepcidin binds ferroportin (the only known cellular iron exporter), causing its internalization and degradation. This single interaction controls iron absorption from the gut, iron recycling from macrophages, and iron release from storage sites. Hepcidin excess causes anemia of chronic disease. Hepcidin deficiency causes hereditary hemochromatosis. Over 6,700 published studies establish the biology.
What is not yet established
Whether hepcidin-targeted therapies (hepcidin mimetics, anti-hepcidin antibodies) will achieve FDA approval. Whether routine hepcidin testing should be incorporated into standard iron panels. Long-term safety of chronic hepcidin pathway modulation.
Research Evidence
The findings below cover the discovery of the hepcidin-ferroportin axis, the clinical conditions it explains, and the therapeutic pipeline targeting this pathway.
Evidence by condition
Evidence dimensions across hepcidin's clinical applications. Iron metabolism has the deepest evidence with complete mechanistic understanding. Anemia of chronic disease and hemochromatosis pathophysiology are fully characterized. Therapeutic hepcidin-targeting agents are in clinical development.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Iron Metabolism | ||||
| Anemia of Chronic Disease | ||||
| Hemochromatosis | ||||
| Iron Overload Disorders |
Hepcidin binds directly to ferroportin (the only known cellular iron exporter) and triggers its internalization and degradation. This single molecular interaction controls all systemic iron flow: absorption from the gut, recycling from macrophages, and release from storage sites.
The Nemeth et al. (2004) Science paper identifying this mechanism is one of the most cited papers in hematology. It explained how one peptide could control the entire iron economy of the body.
Inflammation-driven hepcidin elevation (via the IL-6/STAT3 pathway) is the primary mechanism of anemia of chronic disease, the most common anemia in hospitalized patients. High hepcidin traps iron in macrophages and blocks gut absorption, causing functional iron deficiency despite adequate total body iron.
This discovery explained a clinical puzzle: why patients with chronic infections, autoimmune disease, and cancer develop anemia that does not respond to iron supplementation. The iron is present in the body but inaccessible because hepcidin has locked the exit doors.
Hepcidin deficiency causes hereditary hemochromatosis and iron-loading anemias. HFE (homeostatic iron regulator) mutations (C282Y, H63D) impair hepcidin regulation, allowing unchecked iron absorption that progressively damages the liver, heart, and pancreas.
Hepcidin mimetics (minihepcidins and rusfertide/PTG-300) are being developed to replace the deficient hepcidin signal in these conditions. Phase III trials for polycythemia vera are underway.
12 Human|11 Animal|26 Reviews
View all 49 indexed studiesHow Hepcidin Works
Think of hepcidin as a gatekeeper for iron. It controls a protein called ferroportin, the only exit door for iron to leave cells and enter the bloodstream. When hepcidin is high, it locks the door, trapping iron inside cells. When hepcidin is low, the door stays open and iron flows freely. Inflammation raises hepcidin (causing anemia), and genetic defects that lower hepcidin cause iron overload (hemochromatosis).
Think of hepcidin as a gatekeeper for iron. It controls a protein called ferroportin, the only exit door for iron to leave cells and enter the bloodstream. When hepcidin is high, it locks the door, trapping iron inside cells. Inflammation raises hepcidin, which is why infections and chronic disease cause anemia.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Hepcidin is a 25-amino-acid peptide hormone (8 cysteines forming 4 disulfide bonds) synthesized primarily by hepatocytes. It binds the extracellular loop of ferroportin (SLC40A1), the only known cellular iron exporter, triggering JAK2-mediated phosphorylation, ubiquitination, internalization, and lysosomal degradation. Hepcidin transcription is regulated by the BMP/SMAD pathway (iron status via BMP6), IL-6/STAT3 pathway (inflammation), and erythroferrone (erythropoietic demand, which suppresses hepcidin to increase iron availability for red blood cell production).
What is Hepcidin being studied for?
Researchers are studying Hepcidin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Hepcidin overall. This means a compound can have human studies for one condition but only animal data for another.
Iron Metabolism
·Human TrialsHepcidin is the central regulator of systemic iron homeostasis. The hepcidin-ferroportin axis controls all iron absorption, recycling, and storage. This is among the most well-established findings in peptide endocrinology.
Limitations: Hepcidin testing is not yet part of standard clinical iron panels. Whether routine hepcidin measurement improves clinical decision-making beyond existing iron studies is being evaluated.
Anemia of Chronic Disease
·Human TrialsInflammation-driven hepcidin elevation causes functional iron deficiency by trapping iron in macrophages and blocking gut absorption. This is the primary mechanism of the most common anemia in hospitalized patients.
Limitations: Anti-hepcidin therapies for anemia of chronic disease are investigational. Current treatment focuses on addressing the underlying inflammation rather than targeting hepcidin directly.
Hemochromatosis
·Human TrialsHereditary hemochromatosis results from inappropriately low hepcidin, allowing excessive iron absorption that progressively damages organs. HFE gene mutations impair hepcidin regulation.
Limitations: Current treatment is phlebotomy (blood removal). Hepcidin mimetics are in clinical development but not yet approved.
Iron Overload Disorders
·Animal StudiesHepcidin mimetics (minihepcidins, rusfertide/PTG-300) are being developed to treat iron overload in conditions characterized by hepcidin deficiency, including beta-thalassemia.
Limitations: Hepcidin mimetic therapies are in clinical trials but not yet FDA-approved. Long-term safety of chronic hepcidin pathway modulation is being evaluated.
Safety and Regulatory Status
FDA Status: Hepcidin itself is not FDA-approved as a therapeutic. Hepcidin mimetics (rusfertide) are in Phase III clinical trials. Anti-hepcidin antibodies are in earlier clinical development.
Availability: Naturally occurring (the body's own) liver hormone. Not available as a supplement. Hepcidin testing is available through specialty laboratories.
Class context: Naturally occurring with no safety concerns from normal physiology. Iron metabolism is tightly regulated, and any therapeutic modulation of the hepcidin pathway requires careful calibration to avoid either iron deficiency or iron overload. This is a precision medicine target.
Hepcidin is naturally occurring (the body's own) with no safety concerns from normal physiology. The key consideration for therapeutic development is that iron metabolism is a precision-regulated system. Too much hepcidin causes iron deficiency anemia; too little causes iron overload. Any hepcidin-targeted therapy must carefully calibrate dosing to stay within the physiological range.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Hepcidin discussion.
Comparison and Related Research
Hepcidin is compared with other peptides involved in iron and immune regulation.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.One of the two independent discovery papers for hepcidin (originally named LEAP-1). Researchers isolated this 25-amino-acid peptide from human blood ultrafiltrate and demonstrated its antimicrobial properties against bacteria and fungi. The peptide's four disulfide bonds create an unusually compact and stable structure among antimicrobial peptides.Krause A et al., 2000 in FEBS Lett. View on PubMed
- 2.The companion discovery paper that independently identified hepcidin from human urine and named it for its hepatic origin and antimicrobial properties. This study confirmed liver-specific expression and established the peptide's role in innate immunity. The convergence of these two independent discoveries underscored the biological significance of hepcidin.Park CH et al., 2001 in J Biol Chem. View on PubMed
- 3.Established hepcidin as the master regulator of iron metabolism. Working with iron-overloaded mice, the study showed that hepcidin expression increases in response to iron loading and decreases during iron deficiency. This repositioned hepcidin from an antimicrobial peptide to the central hormonal controller of systemic iron balance.Nicolas G et al., 2002 in Proc Natl Acad Sci U S A. View on PubMed
- 4.Identified the molecular mechanism by which hepcidin controls iron levels. Hepcidin binds directly to ferroportin, the only known cellular iron exporter on cell surfaces, causing it to be internalized and degraded. This single interaction explains how hepcidin controls iron absorption from the gut, iron recycling from macrophages, and iron release from storage sites.Nemeth E et al., 2004 in Science. View on PubMed
- 5.Authoritative review of how the hepcidin-ferroportin axis maintains iron balance across the body. The paper described the regulatory signals that control hepcidin production, including iron status, erythropoietic demand, inflammation, and hypoxia, and how dysregulation of this axis leads to iron overload disorders like hemochromatosis and iron-restricted anemias.Ganz T and Nemeth E., 2012 in Nat Rev Immunol. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.